HBV reactivation in rheumatic diseases patients under therapy: A meta-analysis

Hepatitis B is one of the most common infectious diseases worldwide. In patients undergoing immunosuppressive therapy such as rheumatic diseases, reactivation of hepatitis B virus (HBV) is considered clinically important. This systematic review and meta-analysis were performed to determine the preva...

Full description

Saved in:
Bibliographic Details
Published in:Microbial pathogenesis 2018-01, Vol.114, p.436-443
Main Authors: Moghoofei, Mohsen, Mostafaei, Shayan, Ashraf-Ganjouei, Amir, Kavosi, Hoda, Mahmoudi, Mahdi
Format: Article
Language:English
Subjects:
Antirheumatic Agents - pharmacology
Databases, Factual
DNA, Viral - blood
HBV reactivation
Hepatitis B - complications
Hepatitis B - epidemiology
Hepatitis B virus - drug effects
Hepatitis B virus - pathogenicity
Humans
Immunosuppression Therapy
Immunosuppressive Agents - therapeutic use
Liver - enzymology
Meta-analysis
Rheumatic disease
Rheumatic Diseases - complications
Rheumatic Diseases - drug therapy
Rheumatic Diseases - epidemiology
Tumor Necrosis Factor-alpha - antagonists & inhibitors
Virus Activation - drug effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hepatitis B is one of the most common infectious diseases worldwide. In patients undergoing immunosuppressive therapy such as rheumatic diseases, reactivation of hepatitis B virus (HBV) is considered clinically important. This systematic review and meta-analysis were performed to determine the prevalence rate of HBV reactivation in rheumatic patients from different parts of the world. The authors performed a systematic literature review from several reliable databases including Scopus, ISI Web of Science and PubMed. Furthermore, the keywords of this research were “Hepatitis B virus”, “Rheumatic diseases”, “HBV reactivation”, “Anti-TNF”, “DMARDs” and “Biologic agents”. The authors selected 30 studies out of 983 for the present review. The overall estimation of the prevalence of HBV reactivation was 1.4 (95% confidence interval (CI): 1.3–1.6). Also, the heterogeneity in estimating the pooled prevalence among the studies was shown; Cochran Q test, P 
ISSN:0882-4010
1096-1208
1096-1208
DOI:10.1016/j.micpath.2017.12.014